search
Back to results

Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis

Primary Purpose

Sepsis, Septic Shock

Status
Not yet recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
apigenin
sterilized water
Sponsored by
Zhujiang Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring sepsis, apigenin, septic shock

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: age ≥65 years; meeting the diagnostic criteria of the 2016 International Sepsis Guidelines; subjects who voluntarily participated in this study and signed an informed consent form. Exclusion Criteria: patients who are allergic to the study products; patients who are unable to feed via gastrointestinal nutrition tube.

Sites / Locations

  • Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

apigenin

sterilized water

Arm Description

Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.

Gastric tube injection of 5 ml of sterilized water for injection + conventional standardized treatment, for 4 consecutive days.

Outcomes

Primary Outcome Measures

96-hour Sequential Organ Failure Assessment (SOFA) score
The SOFA score is the Sequential Organ Failure Score, which is used to assess a patient's prognosis by determining the degree of impairment of major organ function. The score is divided into 6 sections: respiratory, coagulation, hepatic, cardiovascular, central nervous system, and renal, and ranges from 0 to 4, with higher SOFA scores associated with a higher incidence of poor prognosis.

Secondary Outcome Measures

inflammatory response(1)
the serum level of C-reactive protein(CRP)
inflammatory response(2)
the serum level of interleukin-6(IL-6)
Duration of use of vasoactive drugs
The duration from the vasoactive drugs administration to the successful cessation in hours( The successful cessation is defined as the attainment of a clinician-prescribed mean arterial pressure target for more than 24-hours without the use of vasoactive drugs.This outcome measure is intended only for patients receiving vasoactive drugs)
liver function(1)
the serum level of Alanine transaminase(ALT)
liver function(2)
the serum level of Aspartate transaminase (AST)
liver function(3)
the serum level of total bilirubin(TBil)
lung function
oxygenation index(PaO2/FiO2),the patients treated with extracorporeal membrane oxygenation will not collect this indicator
kidney function(1)
serum level of Creatinine (Cr)
kidney function(2)
serum level of blood urea nitrogen(BUN)
Indicators of infection
the serum level of procalcitonin(PCT)
The level of lactate
the serum level of lactic acid
The Duration of use of mechanical ventilation (MV)
The duration from the MV administration to the successful cessation in hours( The successful cessation is defined as the termination of MV for more than 48-hours. This outcome measure is intended only for patients receiving MV)
The duration of CRRT
The duration of CRRT therapy in hours
Daily urine output
Daily urine output in milliliters from 0:00 - 24:00
fluid balance
Net fluid intake and output in 24 hours
The length of ICU stay
ICU length of ICU stay

Full Information

First Posted
August 11, 2023
Last Updated
August 13, 2023
Sponsor
Zhujiang Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05999682
Brief Title
Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis
Official Title
Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis: A Single-center, Single-blind, Randomized, Placebo-controlled, Pilot Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhujiang Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In this single-center, randomized, single-blind, placebo-controlled pilot clinical trial. The effect of apigenin on the improvement of organ function will be investigated in elderly patients with sepsis. Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital to identify patients with sepsis based on including and excluding criteria and obtain informed consent and randomize them into groups. The treatment group will be given apigenin tablets 50mg ground with 5ml of sterilized water for intra-gastric tube injection; the control group will be given an equal volume of sterilized water for intra-gastric tube injection. The changes in SOFA score and other clinically meaningful outcomes in 4 days will be collected.
Detailed Description
Investigational drug: Apigenin Study title: Improvement of Organ function by Apigenin in Elderly Patients With Sepsis: A Single-center, Single-blind, Randomized, Placebo-controlled, pilot Clinical Trial Principal Investigator: Zhanguo Liu, professor, Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University Study subjects: Elderly septic/septic shock patients who meet the diagnostic criteria of the 2016 International Sepsis Guidelines. Study objectives: The objective of the study is to determine whether apigenin, compared to placebo, improves organ dysfunction scores (SOFA scores) in elderly septic patients. Study design: A single-center, single-blind, randomized, placebo-controlled pilot Clinical Trial. Method: Apigenin group: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 days or until ICU discharge. Placebo control group: Gastric tube injection of 5 ml of sterilized water for injection + conventional standardized treatment, for 4 days or ICU discharge. Course: 4 days Sample size: 20 The number of study center: 1 Study center: Department of Critical Care Medicine of Zhujiang Hospital, Guangzhou, Guangdong, China Primary endpoint: 96-hour Sequential Organ Failure Assessment (SOFA) score Secondary endpoints: The state of inflammatory response: the serum level of interleukin-6(IL-6) and C-reactive protein (CRP) at 96 h after randomization. The state of liver function: the serum level of transaminase (AST#ALT) #total bilirubin at 96 h after randomization. The state of lung function: oxygenation index (PaO2/FiO2) at 96h after Randomization. The state of kidney function: the serum level of Creatinine (Cr)#blood urea nitrogen (BUN)# at 96 h after randomization. The state of infection: the serum level of procalcitonin (PCT) at 96 h after randomization. The state of circulation system: the serum level of lactate at 96 h after Randomization. The duration of successful cessation of supportive therapies for organ dysfunction including vasoactive agents, mechanical ventilation. The daily urine output#duration of continuous renal replacement therapy (CRRT) #fluid balance. The length of stay in ICU. Safety endpoints: adverse events Serious adverse events

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Septic Shock
Keywords
sepsis, apigenin, septic shock

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Treatment group: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 days or ICU discharge. Control group: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 days or ICU discharge.
Masking
Participant
Masking Description
Single(Participant)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
apigenin
Arm Type
Experimental
Arm Description
Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Arm Title
sterilized water
Arm Type
Placebo Comparator
Arm Description
Gastric tube injection of 5 ml of sterilized water for injection + conventional standardized treatment, for 4 consecutive days.
Intervention Type
Other
Intervention Name(s)
apigenin
Intervention Description
Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Intervention Type
Other
Intervention Name(s)
sterilized water
Intervention Description
Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Primary Outcome Measure Information:
Title
96-hour Sequential Organ Failure Assessment (SOFA) score
Description
The SOFA score is the Sequential Organ Failure Score, which is used to assess a patient's prognosis by determining the degree of impairment of major organ function. The score is divided into 6 sections: respiratory, coagulation, hepatic, cardiovascular, central nervous system, and renal, and ranges from 0 to 4, with higher SOFA scores associated with a higher incidence of poor prognosis.
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Secondary Outcome Measure Information:
Title
inflammatory response(1)
Description
the serum level of C-reactive protein(CRP)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
inflammatory response(2)
Description
the serum level of interleukin-6(IL-6)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
Duration of use of vasoactive drugs
Description
The duration from the vasoactive drugs administration to the successful cessation in hours( The successful cessation is defined as the attainment of a clinician-prescribed mean arterial pressure target for more than 24-hours without the use of vasoactive drugs.This outcome measure is intended only for patients receiving vasoactive drugs)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
liver function(1)
Description
the serum level of Alanine transaminase(ALT)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
liver function(2)
Description
the serum level of Aspartate transaminase (AST)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
liver function(3)
Description
the serum level of total bilirubin(TBil)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
lung function
Description
oxygenation index(PaO2/FiO2),the patients treated with extracorporeal membrane oxygenation will not collect this indicator
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
kidney function(1)
Description
serum level of Creatinine (Cr)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
kidney function(2)
Description
serum level of blood urea nitrogen(BUN)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
Indicators of infection
Description
the serum level of procalcitonin(PCT)
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
The level of lactate
Description
the serum level of lactic acid
Time Frame
The outcome will be assessed at the 0,1,2,3,4 day after enrollment
Title
The Duration of use of mechanical ventilation (MV)
Description
The duration from the MV administration to the successful cessation in hours( The successful cessation is defined as the termination of MV for more than 48-hours. This outcome measure is intended only for patients receiving MV)
Time Frame
The outcome will be assessed at the 28 day after enrollment
Title
The duration of CRRT
Description
The duration of CRRT therapy in hours
Time Frame
The outcome will be assessed at the 28 day after enrollment
Title
Daily urine output
Description
Daily urine output in milliliters from 0:00 - 24:00
Time Frame
The outcome will be assessed at the 1,2,3,4 day after enrollment
Title
fluid balance
Description
Net fluid intake and output in 24 hours
Time Frame
The outcome will be assessed at the 1,2,3,4 day after enrollment
Title
The length of ICU stay
Description
ICU length of ICU stay
Time Frame
The outcome will be assessed at the 28 day after enrollment
Other Pre-specified Outcome Measures:
Title
Incidence of adverse events
Description
A adverse event refers to any adverse medical event that occur after the intervention of trial. The adverse events are not necessarily causally related to the trial treatment.
Time Frame
The outcome will be assessed at the 28 day after enrollment
Title
Incidence of serious adverse events
Description
Any adverse medical event occurs at any dose that meets one or more of the following criteria: 1. causes death 2.life-threatening 3. requires hospitalization or hospitalization for an extended period of time 4. causes permanent or significant disability and functional defects 5. causes deformity.
Time Frame
The outcome will be assessed at the 28 day after enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age ≥65 years; meeting the diagnostic criteria of the 2016 International Sepsis Guidelines; subjects who voluntarily participated in this study and signed an informed consent form. Exclusion Criteria: patients who are allergic to the study products; patients who are unable to feed via gastrointestinal nutrition tube.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhanguo Liu, M.D.PhD
Phone
+862062782927
Email
zhguoliu@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhanguo Liu, M.D.PhD
Organizational Affiliation
Department of Critical Care Medicine of Zhujiang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
City
Guanzhou
State/Province
Guangdong
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhanguo Liu, M.D.PhD
Phone
+862062782927
Email
zhguoliu@163.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
The datasets generated and analyzed during the study are available from the corresponding author on reasonable request.

Learn more about this trial

Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis

We'll reach out to this number within 24 hrs